VC Survey: The biggest impacts of AI on health care?

Hinge Health's IPO raised $437 million, closing its first week above its $32 IPO price, with the CEO emphasizing the company's focus on automating care by reducing clinician hours. Novo Nordisk is partnering with telehealth companies like Ro and LifeMD to promote Wegovy at lower prices, aiming to convert compounded GLP-1 users to branded versions. A Venrock survey indicates that healthcare professionals believe AI's biggest impact will be cutting costs and improving profitability for existing businesses.

Analysis

Hinge Health's recent initial public offering, which successfully raised $437 million and saw its stock close at $37.56 against a $32 IPO price, signals a potentially positive development for the digital health IPO market, even though the company went public at less than half its 2021 valuation. CEO Dan Perez highlighted a strategic focus on automating care, stating the company has eliminated 95% of human clinician hours required for physical therapy, a significant operational efficiency claim. Concurrently, Novo Nordisk (NVO) is actively expanding its market reach for Wegovy by partnering with telehealth companies, including Ro and LifeMD (LFMD), to offer the branded GLP-1 drug at lower cash-pay prices and utilizing limited-time coupons to convert users from compounded versions; this strategy indicates an aggressive push to secure market share. Supporting the theme of technology-driven change, a Venrock survey of 278 healthcare stakeholders revealed a prevailing belief that artificial intelligence will yield a more significant impact on cost reduction and improved profitability—with 44% citing improved profitability as the largest benefit—than on direct care improvement. Further industry activity includes Salvia BioElectrics securing $60 million for its neuromodulation implant for migraines and Otsuka Precision Health hiring to support its prescription digital therapeutic, underscoring continued innovation and investment in targeted health tech solutions. The overall sentiment surrounding these developments is strongly positive, reflecting an optimistic outlook on technological advancements within the healthcare sector.

Key Decisions for Investors

• Monitor the digital health IPO market for further openings, observing valuation trends and the strategic emphasis on care automation as exemplified by Hinge Health.
• Assess Novo Nordisk's (NVO) telehealth partnerships and aggressive pricing for Wegovy as key drivers for potential market share expansion, and evaluate the corresponding impact on telehealth partners like LifeMD (LFMD).
• Prioritize healthcare companies demonstrating clear ROI from AI in terms of cost reduction and profitability, aligning with the Venrock survey's indication of industry expectations.
• Recognize ongoing investment opportunities in specialized health tech sectors such as neuromodulation and prescription digital therapeutics, where innovation continues to attract capital.